Synthesis 2013; 45(17): 2413-2416
DOI: 10.1055/s-0033-1339325
paper
© Georg Thieme Verlag Stuttgart · New York

5,6,7,8-Tetrahydropyrido[4,3-c]pyridazine: A Lead-Oriented Scaffold with Two Diversity Points

Alexander V. Borisov
a   Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Murmanska Street 5, Kyiv 02660, Ukraine
,
Volodymyr V. Voloshchuk
a   Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Murmanska Street 5, Kyiv 02660, Ukraine
b   National Technical University of Ukraine ‘Kyiv Politechnic Institute’, Peremogy Avenue 37, Kyiv 03056, Ukraine
,
Maxim A. Nechayev
c   National University of Pharmacy, Pushkinska Street 53, Kharkiv 61002, Ukraine
,
Oleksandr O. Grygorenko*
d   National Taras Shevchenko University of Kyiv, Volodymyrska Street 64, Kyiv 01601, Ukraine   Fax: +380(44)5732643   Email: gregor@univ.kiev.ua
› Author Affiliations
Further Information

Publication History

Received: 17 April 2013

Accepted after revision: 07 June 2013

Publication Date:
10 July 2013 (online)


Abstract

An approach to the derivatives of 5,6,7,8-tetrahydropyrido[4,3-c]pyridazine, a lead-oriented scaffold with two diversity points, was developed. The method included five steps starting from the readily available 4-piperidone derivatives and allowed for the preparation of the target compounds in 32–35% overall yields. The key step of the sequence included one-pot solvent-free reaction of the corresponding 4-piperidone derivative, glyoxylic acid, and hydrazine.

Supporting Information

 
  • References

    • 1a Heinisch G, Frank H. Prog. Med. Chem. 1990; 27: 1
    • 1b Heinisch G, Kopelent-Frank H. Prog. Med. Chem. 1992; 29: 141
  • 2 Wermuth CG. Med. Chem. Commun. 2011; 2: 935
    • 3a Olsen AG, Dahl O, Nielsen PE. Bioorg. Med. Chem. Lett. 2004; 14: 1551
    • 3b Malnuit V, Duca M, Benhida R. Org. Biomol. Chem. 2011; 9: 326
  • 4 Volonterio A, Moisan L, Rebek JJr. Org. Lett. 2007; 9: 3733
    • 5a Lovering F, Bikker J, Humblet C. J. Med. Chem. 2009; 52: 6752
    • 5b Nicholls A, McGaughey GB, Sheridan RP, Good AC, Warren G, Mathieu M, Muchmore SW, Brown SP, Grant JA, Haigh JA, Nevins N, Jain AN, Kelley B. J. Med. Chem. 2010; 53: 3862
  • 6 Instant JChem was used for prediction of the physico-chemical properties of 1: Instant JChem 3.0, 2009, ChemAxon (http://www.chemaxon.com).
  • 7 Congreve M, Carr R, Murray C, Jhoti H. Drug Discovery Today 2003;  8: 876
  • 8 Grygorenko OO, Radchenko DS, Volochnyuk DM, Tolmachev AA, Komarov IV. Chem. Rev. 2011; 111: 5506
  • 9 Nadin A, Hattotuwagama C, Churcher I. Angew. Chem. Int. Ed. 2012; 51: 1114
  • 10 Salzmann R, Bürki H, Chu D, Clark B, Marbach P, Markstein R, Reinert H, Siegl H, Waite R. Arzneim.-Forsch. 1979; 29: 1843
  • 11 Schenker E, Salzmann R. Arzneim.-Forsch. 1979; 29: 1835
    • 12a Kozikowski AP, Park P. J. Org. Chem. 1990; 55: 4668
    • 12b Masse J, Langlois N. Heterocycles 2009; 77: 417
  • 13 Suzuki K, Senoh A, Ueno K. Heterocycles 2002; 57: 723